cytarabine has been researched along with Esophageal Squamous Cell Carcinoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bi, Y; Cheng, X; Cui, H; Cui, Y; Gao, Y; Guo, M; Kong, P; Li, H; Liu, F; Ma, Y; Niu, X; Qian, Y; Wang, F; Xu, J; Yan, T; Yang, J; Zhang, L; Zhang, X | 1 |
1 other study(ies) available for cytarabine and Esophageal Squamous Cell Carcinoma
Article | Year |
---|---|
TSTA3 facilitates esophageal squamous cell carcinoma progression through regulating fucosylation of LAMP2 and ERBB2.
Topics: Aged; Animals; Carbohydrate Epimerases; Cell Line, Tumor; Cell Proliferation; Disease Progression; DNA Copy Number Variations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycosylation; Guanosine Diphosphate Fucose; Humans; Ketone Oxidoreductases; Lysosomal-Associated Membrane Protein 2; Male; Mice; Middle Aged; Prognosis; Receptor, ErbB-2; Whole Genome Sequencing; Xenograft Model Antitumor Assays | 2020 |